TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06785636: PATHWAY: A Phase 1b/2a, Multicenter, Open- Label Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Sponsor: Pathos AI, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$8,678,670

Rescue Site Savings

+$5,733,420

Unlock Full NCT06785636 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06785636 Rescue Dossier →